215 related articles for article (PubMed ID: 22948772)
1. Alterations of circulating bone marrow-derived VEGFR-2+ progenitor cells in isolated limb perfusion with or without rhTNF-α.
Nowak K; Jachol N; Rafat N; Joas E; Beck GCh; Hohenberger P
Ann Surg Oncol; 2013 Oct; 20(11):3694-701. PubMed ID: 22948772
[TBL] [Abstract][Full Text] [Related]
2. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
Kettelhack C; Hohenberger P; Schulze G; Kilpert B; Schlag PM
Crit Care Med; 2000 Apr; 28(4):1040-6. PubMed ID: 10809279
[TBL] [Abstract][Full Text] [Related]
3. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
4. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
5. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation.
Gutman M; Inbar M; Lev-Shlush D; Abu-Abid S; Mozes M; Chaitchik S; Meller I; Klausner JM
Cancer; 1997 Mar; 79(6):1129-37. PubMed ID: 9070490
[TBL] [Abstract][Full Text] [Related]
6. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
Lienard D; Ewalenko P; Delmotte JJ; Renard N; Lejeune FJ
J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926
[TBL] [Abstract][Full Text] [Related]
7. Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma.
Smith HG; Cartwright J; Wilkinson MJ; Strauss DC; Thomas JM; Hayes AJ
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S356-61. PubMed ID: 26350373
[TBL] [Abstract][Full Text] [Related]
8. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors.
Vrouenraets BC; Keus RB; Nieweg OE; Kroon BB
J Surg Oncol; 1997 Jun; 65(2):88-94. PubMed ID: 9209519
[TBL] [Abstract][Full Text] [Related]
9. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
[TBL] [Abstract][Full Text] [Related]
10. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
Kettelhack C; Hohenberger P; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
[TBL] [Abstract][Full Text] [Related]
11. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma.
Grunhagen DJ; de Wilt JH; Graveland WJ; van Geel AN; Eggermont AM
Cancer; 2006 Jan; 106(1):156-62. PubMed ID: 16323177
[TBL] [Abstract][Full Text] [Related]
12. Lower limb function and quality of life after ILP for soft-tissue sarcoma.
Podleska LE; Kaya N; Farzaliyev F; Pöttgen C; Bauer S; Taeger G
World J Surg Oncol; 2017 Apr; 15(1):84. PubMed ID: 28403880
[TBL] [Abstract][Full Text] [Related]
13. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
[TBL] [Abstract][Full Text] [Related]
14. [Assessment of regional and systemic toxicity of isolated hyperthermic extremity perfusion with tumor necrosis factor-alpha and melphalan].
Hohenberger P; Haier J; Kettelhack C; Schulze G; Schlag PM
Chirurg; 1997 Sep; 68(9):914-20. PubMed ID: 9410682
[TBL] [Abstract][Full Text] [Related]
15. Rhabdomyolysis and renal function impairment after isolated limb perfusion--comparison between the effects of perfusion with rhTNF alpha and a 'triple-drug' regimen.
Hohenberger P; Haier J; Schlag PM
Eur J Cancer; 1997 Apr; 33(4):596-601. PubMed ID: 9274441
[TBL] [Abstract][Full Text] [Related]
16. Transient induction of E-selectin expression following TNF alpha-based isolated limb perfusion in melanoma and sarcoma patients is not tumor specific.
Nooijen PT; Eggermont AM; Verbeek MM; Schalkwijk L; Buurman WA; de Waal RM; Ruiter DJ
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):33-44. PubMed ID: 8859722
[TBL] [Abstract][Full Text] [Related]
17. Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
Hohenberger P; Latz E; Kettelhack C; Rezaei AH; Schumann R; Schlag PM
Ann Surg Oncol; 2003 Jun; 10(5):562-8. PubMed ID: 12794024
[TBL] [Abstract][Full Text] [Related]
18. [Procalcitonin as marker of systemic inflammatory reaction after isolated extremity perfusion].
Kettelhack C; Hohenberger P; Furchtbar S; Schulze G; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):399-402. PubMed ID: 14518284
[TBL] [Abstract][Full Text] [Related]
19. Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection.
Jakob J; Tunn PU; Hayes AJ; Pilz LR; Nowak K; Hohenberger P
J Surg Oncol; 2014 Jun; 109(8):786-90. PubMed ID: 24619722
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human tumor necrosis factor: an efficient agent for cancer treatment.
Lejeune FJ; Rüegg C
Bull Cancer; 2006 Aug; 93(8):E90-100. PubMed ID: 16935777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
